Andrea Bernetti1, Massimiliano Mangone2, Ciro Villani3, Federica Alviti2, Massimo Valeo3, Maria C Grassi4,5, Alberto Migliore6, Ugo Viora7, Ezio Adriani8, Nicola Quirino9, Antonella Fioravanti10, Marco Paoloni2. 1. Department of Physical Medicine and Rehabilitation, Sapienza University, Rome, Italy - andrea.bernetti@uniroma1.it. 2. Department of Physical Medicine and Rehabilitation, Sapienza University, Rome, Italy. 3. Department of Orthopedic Science, Sapienza University, Rome, Italy. 4. Vittorio Erspamer Department of Physiology and Pharmacology, Sapienza University, Rome, Italy. 5. Unit of Drug Addiction and Clinical Pharmacology, Umberto I University Hospital, Sapienza University, Rome, Italy. 6. San Pietro Fatebenefratelli Hospital, Rome, Italy. 7. Associazione Nazionale Malati Reumatici Onlus (ANMAR), Rome, Italy. 8. Department of Orthopedics and Traumatology, Sport Clinique, Rome, Italy. 9. LUISS University, Rome, Italy. 10. Unit of Rheumatology, Department of Medicine, Surgery and Neurosciences, Le Scotte Polyclinic, University of Siena, Siena, Italy.
Abstract
BACKGROUND: Osteoarthritis (OA) is a theme currently representing an emerging topic for its increasing incidence. It is well known that it is a chronic disease that could lead to important long-lasting disability; this generates increasing costs for the health care system. OA treatment options vary: localization, etiology, grading and symptomatology should be considered before choosing the most adequate therapy. Currently, a modern approach to managing OA involves SYmptomatic Slow-Acting Drug for OsteoArthritis (SYSADOAs). However, while all preparations may claim to deliver a therapeutic level of glucosamine or chondroitin, not all of them are supported by clinical evidence. Recently the European Society for Clinical and Economic aspects of Osteoporosis, Osteoarthritis and musculoskeletal diseases (ESCEO), produced an evidenced based document providing practitioners with the latest clinical and economic information, thereby allowing them to optimize the management of knee OA. According to this report, only crystalline glucosamine sulphate and the pharmaceutical-grade chondroitin sulphate are considered as effective in the first line approach to treating knee OA as an alternative drug to acetaminophen. However, some OA guidelines do not agree are not concordant in recommending the use of SYSADOA, perhaps because they are generally considered as a class and distinctions among formulations are not made. AIM: Aim of this study was to identify the main aspects involved in patient selection, the choice of therapeutic agents and the safety profile in using SYSADOA. DESIGN: Delphi method Consenus Statement. POPULATION: Italian Physicians having expertise in Osteoarthritis management. METHODS: A committee of 11 experts from Italian universities, public hospitals, territorial services, research institutes and patient associations was set up. Sixty-three clinicians from a large number of Italian medical centers specialized in osteoarthritis management took part in a Delphi process which was aimed at obtaining consensus statements among the participants. RESULTS: Large consensus was obtained for statements grouped under the following main themes: treatment indications; drug/medical devices choice; treatment efficacy. CONCLUSIONS: Results from the Italian consensus on appropriateness of OA therapies in osteoarthritis seems to be in line with the stepwise approach proposed by the ESCEO algorithm, where crystalline glucosamine sulphate shows greater clinical efficacy than other glucosamine-based formulations, according to several independent meta-analyses. CLINICAL REHABILITATION IMPACT: This study may be used as a practical reference tool to help Italian physicians treat osteoarthritis patients using SYSADOA.
BACKGROUND:Osteoarthritis (OA) is a theme currently representing an emerging topic for its increasing incidence. It is well known that it is a chronic disease that could lead to important long-lasting disability; this generates increasing costs for the health care system. OA treatment options vary: localization, etiology, grading and symptomatology should be considered before choosing the most adequate therapy. Currently, a modern approach to managing OA involves SYmptomatic Slow-Acting Drug for OsteoArthritis (SYSADOAs). However, while all preparations may claim to deliver a therapeutic level of glucosamine or chondroitin, not all of them are supported by clinical evidence. Recently the European Society for Clinical and Economic aspects of Osteoporosis, Osteoarthritis and musculoskeletal diseases (ESCEO), produced an evidenced based document providing practitioners with the latest clinical and economic information, thereby allowing them to optimize the management of knee OA. According to this report, only crystalline glucosamine sulphate and the pharmaceutical-grade chondroitin sulphate are considered as effective in the first line approach to treating knee OA as an alternative drug to acetaminophen. However, some OA guidelines do not agree are not concordant in recommending the use of SYSADOA, perhaps because they are generally considered as a class and distinctions among formulations are not made. AIM: Aim of this study was to identify the main aspects involved in patient selection, the choice of therapeutic agents and the safety profile in using SYSADOA. DESIGN: Delphi method Consenus Statement. POPULATION: Italian Physicians having expertise in Osteoarthritis management. METHODS: A committee of 11 experts from Italian universities, public hospitals, territorial services, research institutes and patient associations was set up. Sixty-three clinicians from a large number of Italian medical centers specialized in osteoarthritis management took part in a Delphi process which was aimed at obtaining consensus statements among the participants. RESULTS: Large consensus was obtained for statements grouped under the following main themes: treatment indications; drug/medical devices choice; treatment efficacy. CONCLUSIONS: Results from the Italian consensus on appropriateness of OA therapies in osteoarthritis seems to be in line with the stepwise approach proposed by the ESCEO algorithm, where crystalline glucosamine sulphate shows greater clinical efficacy than other glucosamine-based formulations, according to several independent meta-analyses. CLINICAL REHABILITATION IMPACT: This study may be used as a practical reference tool to help Italian physicians treat osteoarthritispatients using SYSADOA.
Authors: Marco Paoloni; Francesco Agostini; Sergio Bernasconi; Gianni Bona; Carlo Cisari; Massimo Fioranelli; Marco Invernizzi; Antonello Madeo; Marco Matucci-Cerinic; Alberto Migliore; Nicola Quirino; Carlo Ventura; Roberto Viganò; Andrea Bernetti Journal: Medicina (Kaunas) Date: 2022-01-14 Impact factor: 2.430